
Thought rising yields meant falling demand?
Tomlin_Ashcroft
3.6K posts

@tomlin_ashcroft
not advice. not anything. a nobody of Twitter.

Thought rising yields meant falling demand?

MOTS-C APPROVED!!! 4/4 today. Day 1 in the books. Semax, epitalon, and DSIP up tomorrow.

$HIMS 🚨 BREAKING: FDA PEPTIDES PANEL VOTES "YES" ON ALL 4 PEPTIDES UNDER REVIEW TODAY BPC-157 KPV TB-500 MOTS-C

$AMGN Amgen is facing a classic pharmaceutical growth dilemma: an impending "patent cliff" and mixed pipeline progress (notably in obesity treatments) are threatening revenue growth. To replace lost revenue, Amgen may be forced to turn to debt-funded M&A. $XBI The Patent Cliff Exposure: Amgen faces $28 billion in expiring drug patents between 2025 and 2030, representing its highest peer-group exposure and risking up to 30% of total revenue erosion. Available Debt Capacity: Amgen can comfortably borrow up to $12 billion in new debt raising its leverage to roughly 3.25x without triggering credit rating downgrades below its current high-triple-B rating (Baa1 / BBB+). EBITDA Expansion: Earnings before interest, taxes, depreciation, and amortization (EBITDA) are projected to grow significantly, reaching over $20 billion in 2026 (up from $14 billion in 2025). Track Record of Deleveraging: Amgen demonstrated strong balance sheet discipline after acquiring Horizon Therapeutics for $27 billion in 2023, taking leverage to nearly 5x before bringing it back down to low-3x within two years. Rating Agency Hesitation: Credit rating agencies (Moody's, S&P, Fitch) are likely to scrutinize new debt heavily due to the impending revenue drops between 2026 and 2030. Image Credits: @bioinvestor24

My latest article just came out in Reason! It's all about what the government is doing and what it ought to do about antidepressants. Right now, it looks like they're poised to cause a lot of harm by acting hastily, but, I argue, they need to slow down and gather more data.



Loaded $CMPS. Another CNS PHIII super fail or a potential darling in a market of virtually nothing innovative? Only one who picked it in #biopick2026, which was really surprising. Last lone soldier pick was $KRTX … Let’s see if we can have some fun 😊

$TGTX Initiates Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia


$LLY oral is gonna be fine. chill tf out Keenan




heavy deadlift is probably the worst exercise for a non athlete man in terms of risk and reward the risk is literally breaking your back for life against the reward of posting your videos on instagram circle







getting ~12 requests per day for expert calls on ai x bio, folks really trying to understand the space
